EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle

Ann Oncol. 2012 May;23(5):1370-1371. doi: 10.1093/annonc/mds031. Epub 2012 Mar 1.

Authors

L Fornaro¹, F Crea², G Masi³, E Paolicchi², F Loupakis³, F Graziano⁴, L Salvatore³, M Ronzoni⁵, V Ricci⁵, C Cremolini³, M Schirripa³, R Danesi², A Falcone³

Affiliations

¹ Department of Oncology, Transplants and New Technologies in Medicine, Division of Medical Oncology, University of Pisa, Pisa. Electronic address: lorenzo.fornaro@gmail.com.
² Department of Internal Medicine, Division of Pharmacology, University of Pisa, Pisa.
³ Department of Oncology, Transplants and New Technologies in Medicine, Division of Medical Oncology, University of Pisa, Pisa.
⁴ Medical Oncology Unit, Department of Onco-Hematology, Azienda Ospedaliera S. Salvatore, Pesaro.
⁵ Division of Medical Oncology, S. Raffaele Scientific Institute, Milano, Italy.

PMID: 22383679
DOI: 10.1093/annonc/mds031

No abstract available

Publication types

Evaluation Study
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Antibodies, Monoclonal, Humanized / administration & dosage*
Antibodies, Monoclonal, Humanized / adverse effects*
Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Bevacizumab
Camptothecin / administration & dosage
Camptothecin / adverse effects
Camptothecin / analogs & derivatives
Camptothecin / therapeutic use
Carcinoma / diagnosis
Carcinoma / drug therapy*
Carcinoma / genetics
Carcinoma / mortality
Colorectal Neoplasms / diagnosis
Colorectal Neoplasms / drug therapy*
Colorectal Neoplasms / genetics
Colorectal Neoplasms / mortality
DNA-Binding Proteins / genetics*
Enhancer of Zeste Homolog 2 Protein
Fluorouracil / administration & dosage
Fluorouracil / adverse effects
Fluorouracil / therapeutic use
Genotype
Humans
Leucovorin / administration & dosage
Leucovorin / adverse effects
Leucovorin / therapeutic use
Middle Aged
Polycomb Repressive Complex 2
Polymorphism, Single Nucleotide* / physiology
Prognosis
Risk Assessment
Survival Analysis
Transcription Factors / genetics*

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents
DNA-Binding Proteins
Transcription Factors
Bevacizumab
EZH2 protein, human
Enhancer of Zeste Homolog 2 Protein
Polycomb Repressive Complex 2
Leucovorin
Fluorouracil
Camptothecin

Supplementary concepts

IFL protocol